Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration

Brain Research

Volumn 1168, Issue 1, 2007, Pages 83-89

  Mathur, Brian N ^a   Neely, M Diana ^a   Dyllick Brenzinger, Melanie ^b   Tandon, Anurag ^b   Deutch, Ariel Y ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Parkinson's disease; PSI; Striatum; Substantia nigra; Tyrosine hydroxylase

Indexed keywords

DOPAMINE; PROTEASOME; PROTEASOME INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CELL CULTURE; CELL INCLUSION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; MALE; MASS SPECTROMETRY; MESENCEPHALON; MOTOR DYSFUNCTION; NEUROTOXICITY; NEWBORN; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; STRIATONIGRAL DEGENERATION;

ANIMALS; ANIMALS, NEWBORN; CORPUS STRIATUM; CYSTEINE PROTEINASE INHIBITORS; DOPAMINE; MALE; MOTOR ACTIVITY; NERVE DEGENERATION; OLIGOPEPTIDES; ORGAN CULTURE TECHNIQUES; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA;

ANIMALIA; RATTUS;

EID: 34548283619     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2007.06.076     Document Type: Article

References (29)

1. Beal F., and Lang A. The proteasomal inhibition model of Parkinson's disease: "boon or bust"?. Ann. Neurol. 60 (2006) 158-161
2. Betarbet R., Sherer T.B., and Greenamyre J.T. Ubiquitin-proteasome system and Parkinson's diseases. Exp. Neurol. 191 (2005) S17-S27
3. Bove J., Zhou C., Jackson-Lewis V., Taylor J., Chu Y., Rideout H.J., Wu D.C., Kordower J.H., Petrucelli L., and Przedborski S. Proteasome inhibition and Parkinson's disease modeling. Ann. Neurol. 60 (2006) 260-264
4. Braun H.A., Umbreen S., Groll M., Kuckelkorn U., Mlynarczuk I., Wigand M.E., Drung I., Kloetzel P.M., and Schmidt B. Tripeptide mimetics inhibit the 20 S proteasome by covalent bonding to the active threonines. J. Biol. Chem. 280 (2005) 28394-28401
5. Dauer W., and Przedborski S. Parkinson's disease: mechanisms and models. Neuron 39 (2003) 89-90
6. Dawson T.M., and Dawson V.L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 302 (2003) 819-822
7. Deutch A.Y., Tam S.-Y., and Roth R.H. Footshock and conditioned stress increase 3,4-dihydroxyphenylacetic acid (DOPAC) in the ventral tegmental area but not substantia nigra. Brain Res. 333 (1985) 143-146
8. Deutch A.Y., and Cameron D.S. Pharmacological characterization of dopamine systems in the nucleus accumbens core and shell. Neuroscience 46 (1992) 49-56
9. Elkon H., Melamed E., and Offen D. Oxidative stress, induced by 6-hydroxydopamine, reduces proteasome activities in PC12 cells: implications for the pathogenesis of Parkinson's disease. J. Mol. Neurosci. 24 (2004) 387-400
10. Fornai F., Lenzi P., Gesi M., Fornai F., Lenzi P., Gesi M., Ferrucci M., Lazzeri G., Busceti C.L., Ruffoli R., Soldani P., Ruggieri S., Alessandri M.G., and Paparelli A. Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition. J. Neurosci. 23 (2003) 8955-8966
11. Fornai F., Schluter O.M., Lenzi P., Gesi M., Ruffoli R., Ferrucci M., Lazzeri G., Busceti C.L., Pontarelli F., Battaglia G., Pellegrini A., Nicoletti F., Ruggieri S., Paparelli A., and Sudhof T.C. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and α-synuclein. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 3413-3418
12. Giason B.L., Duda J.E., Murray I.V., Chen Q., Souza J.M., Hurtig H.I., Ischiropoulos H., Trojanowski J.Q., and Lee V.M. Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions. Science 290 (2000) 985-989
13. Hoglinger G.U., Carrard G., Michel P.P., Medja F., Lombes A., Ruberg M., Friguet B., and Hirsch E.C. Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease. J. Neurochem. 86 (2003) 1297-1307
14. Inden M., Kondo J., Kitamura Y., Takata K., Nishimura K., Taniguchi T., Sawada H., and Shimohama S. Proteasome inhibitors protect against degeneration of nigral dopaminergic neurons in hemiparkinsonian rats. J. Pharm. Sci. 97 (2005) 203-211
15. Kordower J.H., Kanaan N.M., Chu Y., Suresh Babu R., Stansell III J., Terpstra B.T., Sortwell C.E., Steece-Collier K., and Collier T.J. Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys. Ann. Neurol. 60 (2006) 264-268
16. Manning-Bog A.B., Reaney S.H., Chou V.P., Johnston L.C., McCormack A.L., Johston J., Langston J.W., and Di Monte D.A. Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Ann. Neurol. 60 (2006) 256-260
17. McNaught K.S., and Olanow C.W. Proteasome inhibitor-induced model of Parkinson's disease. Ann. Neurol. 60 (2006) 243-247
18. McNaught K.S., Mytilineou C., Jonbaptiste R., Yabut J., Shashidharan P., Jenner P., and Olanow C.W. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J. Neurochem. 81 (2002) 301-306
19. McNaught K.S., Perl D.P., Brownell A.L., and Olanow C.W. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann. Neurol. 56 (2004) 149-162
20. Miwa H., Kubo T., Suzuki A., Nishi K., and Kondo T. Retrograde dopaminergic neuron degeneration following intrastriatal proteasome inhibition. Neurosci. Lett. 380 (2005) 93-98
21. Petrucelli L., O'Farrell C., Lockhart P.J., Baptista M., Kehoe K., Vink L., Choi P., Wolozin B., Farrer M., Farrer M., Hardy J., and Cookson M.R. Parkin protects against the toxicity associated with mutant α-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 36 (2002) 1007-1019
22. Rideout H.J., Lang-Rollin I.C., Savalle M., and Stefanis L. Dopaminergic neuron in rat ventral midbrain cultures undergo selective apoptosis and form inclusions, but do not upregulate iHSP70 following proteasomal inhibition. J. Neurochem. 93 (2005) 1304-1313
23. Sawada H., Kohno R., Kihara T., Izumi Y., Sakka N., Ibi M., Nakanishi M., Nakamizo T., Yamakawa K., Shibasaki H., Yamamoto N., Akaike A., Inden M., Kitamura Y., Taniguchi T., and Shimohama S. Proteasome mediates dopaminergic neuronal degeneration, and its inhibition causes α-synuclein inclusions. J. Biol. Chem. 279 (2004) 10710-10719
24. Schapira A.H., Cleeter M.W., Muddle J.R., Workman J.M., Cooper J.M., and King R.H. Proteasome inhibition causes loss of nigral tyrosine hydroxylase neurons. Ann. Neurol. 60 (2006) 253-255
25. Setsuie R., Kabuta T., and Wada K. Does proteosome inhibition decrease or accelerate toxin-induced dopaminergic neurodegeneration?. J. Pharm. Sci. 97 (2005) 457-460
26. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., Lincoln S., Crawley A., Hanson M., Maraganore D., Adler C., Cookson M.R., Muenter M., Baptista M., Miller D., Blancato J., Hardy J., and Gwinn-Hardy K. α-Synuclein locus triplication causes Parkinson's disease. Science 302 (2003) 841
27. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., and Goedert M. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 6469-6473
28. Stoppini L., Buchs P.A., and Muller D. A simple method for organotypic cultures of nervous tissue. J. Neurosci. Methods 37 (1991) 173-182
29. Zeng B.Y., Bukhatwa S., Hakima A., Rose S., and Jenner P. Reproducible nigral cell loss after systemic proteasomal inhibitor administration in rats. Ann. Neurol. 60 (2006) 248-252